Cost-Utility Analysis and Efficiency Frontier of Drugs Available in Brazil for the Treatment of Relapsing-Remitting Multiple Sclerosis
Abstract
In the original published version of this article, errors were introduced during the copyediting process. Please view the full text article to view the list of errors and corrections that were made.
Authors